Development of humanized NOG mice reconstituted with human hepatocytes and their applications in drug discovery and infectious disease research.
| Project/Area Number |
17300136
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory animal science
|
|---|
| Research Institution | Central Institute for Experimental Animals |
|---|
Principal Investigator |
SUEMIZU Hiroshi Central Institute for Experimental Animals, Laboratory Head, バイオメディカル研究部, 室長 (40332209)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKAMURA Masato Tokai University, School of Medicine, Professor, 医学部, 教授 (00164335)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥15,200,000 (Direct Cost: ¥15,200,000)
Fiscal Year 2006: ¥6,500,000 (Direct Cost: ¥6,500,000)
Fiscal Year 2005: ¥8,700,000 (Direct Cost: ¥8,700,000)
|
|---|
| Keywords | immunodeficient NOG mice / liver regeneration / hepatocytes transplantation |
|---|
| Research Abstract |
The aim of this study, which was designed to establish a drug evaluation model and infectious disease model, was "to develop a reconstituted mouse with human hepatocytes". The research plan consisted of the following three steps, and the results at each step are described.
First step : Development of genetically modified mice with sustained hepatic injury.
We established a transgenic mouse (Alb-HSV-Tk), which carries the herpes simplex virus thymidine kinase gene with an albumin enhancer and promoter, to induce hepatocyte specific cell injury by ganciclovir (GCV). Two-hundred and eight pups were obtained by DNA microinjection experiments and we succeeded in obtaining 9 founder mice that showed positive reactions in the first screening by the PCR genotyping test.
Second step : Induction of hepatocyte specific cell injury by GCV administration.
Transgenic pups were obtained from nine Alb-HSV-Tk founders, and the ability to induce hepatic injury by GCV injection was examined. According to the results, elevated levels of AST and ALT were observed only in the Tg-Alb-HSV-Tk #7-2 line (Tg-Tk#7-2). Furthermore, Tg-Tk#7-2 showed apparent jaundice in the ears. Histological investigation of the mouse liver revealed a number of abnormalities, including hepatocyte vaculation and hepatocyte megalocytosis.
Third step : Application in a drug evaluation study with reconstituted mice with human hepatocytes.
Unfortunately, the third step could not be completed within the planned period. The main reason was the sterility in the Tg-Tk#7-2 line, which made large-scale production using in vitro fertilization and embryo transplantation techniques impossible, and drastically delayed our production plan. However, we obtained a few Tg-Tk#7-2 NOG mice, and have already started a human hepatocyte transplantation experiment with weekly evaluations for signs of humanization (Hu-Liver NOG). The Hu-Liver NOG mouse will be a useful model to facilitate the evaluation of drug efficacy and pharmacokinetics.
|
Report
(3 results)
Research Products
(14 results)
